Status:
COMPLETED
COPANLISIB (BAY80-6946) Drug-drug Interaction and Cardiovascular Safety Study in Advanced Solid Tumor and Non-Hodgkin's Lymphoma Patients
Lead Sponsor:
Bayer
Conditions:
Medical Oncology
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
To evaluate the effect of itraconazole or rifampin on the absorption, distribution, metabolism and elimination of COPANLISIB (BAY80-6946). To evaluate the effect of copanlisib on QT/QTc intervals and...
Eligibility Criteria
Inclusion
- Male or female patients ≥ 18 years of age with histological or cytological confirmed advanced solid tumors or non-Hodgkin's lymphoma that have progressed on, or failed to respond to, therapies known to provide clinical benefit may be enrolled after signing informed consent.
- Normal left ventricular ejection fraction; adequate liver, renal and bone-marrow functions as assessed by laboratory values.
- Adequate performance status and life expectancy of at least 3 months.
Exclusion
- Solid-tumor patients with central nervous system (CNS) metastases if treatment completed \< 3 months before enrollment or lesions unstable or progressing on MRI scans performed within 1 month of enrollment or unstable symptoms of the CNS metastases.
- Evidence of ventricular dysfunction such as congestive heart failure (CHF) or a history of CHF greater than NYHA Class II
- Active coronary artery disease or myocardial infarction within the 6 months before study entry; any new-onset angina within the 3 months before study entry or unstable angina; cardiac arrhythmia requiring anti-arrhythmic therapy.
- Prior diagnosis of Type 1 or 2 diabetes mellitus, hyperglycemia (defined as fasting blood or plasma glucose above 125 mg/dL under 2 separate days, corresponding to 6.94 mmol/L) or HbA1c ≥ 7%.
- Use of systemic including inhaled corticosteroids within the 2 days before the start of study treatment (however, topical steroids are permitted).
- Known presence of human immunodeficiency virus (HIV) infection or active hepatitis (B or C).
- Uncontrolled hypertension (systolic blood pressure \[BP\] \>150 mmHg or diastolic blood pressure \> 90 mmHg despite optimal medical management).
- Anticancer chemotherapy, hormone therapy or immunotherapy within the 4 weeks before the first study treatment or scheduled for administration (of the above) during the study
- History of, or concurrent, interstitial lung disease (ILD) or severely impaired pulmonary function.
- Medications with drug-drug interaction potential for itraconazole which is to be excluded before the study and during Cycle 1 such as CYP3A4 substrates with a narrow therapeutic window or which have the potential to prolong QTc
- Concomitant medication contraindicated for use with rifampin (including, but not limited to): cisapride, oral midazolam, nisoldipine, pimozide, quinidine, dofetilide, triazolam, levacetylmethadol (levomethadyl), 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA)-reductase inhibitors metabolised by CYP3A4, such as lovastatin and simvastatin, ergot alkaloids metabolised by CYP3A4, such as dihydroergotamine, ergometrine (ergonovine), ergotamine and methylergometrine (methylergonovine), atazanavir, darunavir, fosamprenavir, ritonavir-boosted saquinavir, saquinavir, or tipranavir
Key Trial Info
Start Date :
October 8 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 13 2019
Estimated Enrollment :
51 Patients enrolled
Trial Details
Trial ID
NCT02253420
Start Date
October 8 2014
End Date
August 13 2019
Last Update
December 14 2020
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Dallas, Texas, United States, 75230
2
Edmonton, Alberta, Canada, T6G 1Z2
3
Vancouver, British Columbia, Canada, V5Z 4E6
4
Hamilton, Ontario, Canada, L8V 5C2